

## MESA MIND Protocol Appendix - Detailed CT/PET Imaging Protocol

<u>Amyloid PET Brain Imaging</u>. Participants who enroll will complete a amyloid imaging protocol with the FDA approved [18F] Florbetaben (Neuroceq ®), which is similar to that used by the Alzheimer's Disease Neuroimaging Initiative – Study (ADNI). Participants will not receive the results from this scan unless so indicated by a clinically significant medical finding.

- Participants will report to the imaging facilities.
- Vital signs (blood pressure, heart rate, temperature) and body weight will be measured on the same day of tracer injection.
- [18F] Florbetaben Participants will be injected with an intravenous bolus of approximately 8 mCi of tracer (minimum 5 mCi / maximum 8.8 mCi). This is the standard dose used in the many published clinical reports using [18F] Florbetaben. After injection, participant will wait for an uptake period of 90 minutes before the tomographic image acquisition begins.
- Participants will be positioned in the PET/CT scanner by trained staff. Participants will be monitored via audio micorphone and video. During PET imaging, participants must remain as still as possible and thus every effort will be made to provide for their comfort including blankets, pillows and diligent assessment. The PET brain imaging procedure is similar to that used by large multicenter imaging clinical trials. Scanning will begin with a standard low dose CT transmission scan of the head that will be used to correctly position the participant and for attenuation correction. Brain emission images will be acquired continuously for a 20 minute period as four 5-minute frames. The images will be immediately assessed for technical validity by the PET technologist and if considered inadequate due to motion or other artifact, the participant will have an additional 20 minutes of continuous imaging, collected as four 5-minute frames.
- From the time of tracer injection until after the imaging session is complete, participants will be observed continuously for signs of adverse events or serious adverse events. The injection site will be observed for excessive inflammation or damage to the surrounding tissue.
- A physician or a person designated by the physician with appropriate training and experience will be present during the tracer injection and to approve discharge of the participant from the PET suite.



## Exam 7 Brain PET Acquisition

Participant ID #:					Acrostic:*							
							*Do	not e	enteri	nto Pl	ET soft	ware
Technician ID:			[	Date	::			/				
					Month	D	ay			Ye	ar	

1. PET tech ID:  2. Time of today's scanner QC:  O AM O PM	Participant Information  3. Sex:
Pre-scan Vitals  5. Blood pressure:/  6. Pulse: bpm	<ul> <li>15. Was appropriate time allowed for tracer uptake?</li> <li>No</li> <li>Yes, 40 minutes for (11C) PiB</li> <li>Yes, 90 minutes for (18F) Florbetaben</li> </ul>
7. Weight: lbs  8. Temperature: °F  Tracer: O (11C) PiB O (18F) florbetaben  9. Dose: mCi  10. Dose assay time: O AM O PM	16. Scan start time:  17. Any variations from protocol during tracer uptake?  Yes If yes, note below (Q29)  No  18. Was the scan completed?  Yes
11. Dose injection time: O AM O PM  12. Residual: mCi  12.1 Residual O AM O PM  Assay Time:	O No If no, note below (Q29)  Post-scan Vitals  19. Blood pressure:/  20. Pulse: bpm
Post-injection Vitals  13. Blood pressure:/  14. Pulse: bpm	



Additional measurements, if necessary:
21. Blood pressure:/
22. Pulse: bpm
23. Blood pressure:/
24. Pulse: bpm
25. Injection site <u>location</u> and <u>observations</u> :
26. Participant encouraged to void and drink plenty of fluids the rest of the day?
O Yes
O No
27. PET technician signature:
28. Notes:

CALL STUDY STAFF PRIOR TO RELEASING PARTICIPANT. [Insert site contact name and phone]